Genocea Biosciences Starts Dosing In Mid-Stage GEN-011 Study In Solid Tumors

  • Genocea Biosciences Inc GNCA has dosed the first patient in its TiTAN Phase 1/2a study, evaluating its GEN-011 therapy in solid tumors.
  • TiTAN is an open-label, multi-center trial evaluating the safety, tolerability, T cell persistence, proliferation, and clinical efficacy. 
  • The trial is testing two dosing regimens, a repeated lower dose regimen of GEN-011 without lymphodepletion and a single high dose administration of GEN-011 after lymphodepletion. 
  • Both groups will receive interleukin-2 after GEN-011 dosing.
  • Initial data from the TiTAN trial is expected in late 4Q of 2021 or Q1 of 2022.
  • GEN-011 represents a category of autologous solid tumor cell therapy: neoantigen-targeted peripheral T cells (NPTs).
  • GEN-011 is a next-generation solid tumor therapy comprised of NPTs CD4+ and CD8+, specific for up to 30 antigens to limit tumor escape. 
  • Price Action: GNCA shares are down 1.49% at $2.06 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsSolid Tumor
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!